BPC-157 / KPV / TB-500.
A three-peptide protocol that adds inflammation modulation to soft-tissue recovery.
3 mg / 3 mg / 3 mg per mL · single-vial injectablePricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Patients with concurrent recovery and inflammatory concerns
- Patients whose injuries are paired with gut irritation or food sensitivities
- Patients with skin and connective-tissue inflammation
- Patients who haven't fully responded to BPC-157 / TB-500 alone
This isn't for you if
Investigational combination. Not appropriate during pregnancy, breastfeeding, or with active malignancy. Components are dispensed through 503A compounding pharmacies.
BPC-157 / KPV / TB-500
This three-peptide combination builds on the Wolverine base by adding KPV — a short anti-inflammatory tripeptide derived from alpha-MSH. It's used when both recovery and inflammation are clinical priorities.
Mechanism and fit.
BPC-157 and TB-500 drive the tissue-repair side: angiogenesis, cell migration, and connective-tissue rebuilding. KPV calms the inflammatory signaling that often stalls healing — particularly when gut inflammation, food sensitivity, or systemic inflammation is part of the picture. The result is a protocol that repairs tissue and the environment around it simultaneously.
Who this is typically for.
- Patients with concurrent recovery and inflammatory concerns
- Patients whose injuries are paired with gut irritation or food sensitivities
- Patients with skin and connective-tissue inflammation
- Patients who haven't fully responded to BPC-157 / TB-500 alone
What patients
most often ask.
Do I need the KPV if I don't have gut issues?
Not necessarily. KPV adds the most value when inflammation — gut, skin, or systemic — is part of the picture. If recovery is your only goal, the two-peptide Wolverine Stack may be sufficient. Your provider will help match the protocol to your clinical picture.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Patients with concurrent recovery and inflammatory concerns</li><li>Patients whose injuries are paired with gut irritation or food sensitivities</li><li>Patients with skin and connective-tissue inflammation</li><li>Patients who haven't fully responded to BPC-157 / TB-500 alone</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingOnce daily, provider-directed, 5 days on / 2 days off.
- Typical duration6–8 weeks per cycle.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering BPC-157 / KPV / TB-500, the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.